<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>AI-driven Structure-enabled Antiviral Platform (ASAP) on ASAP Discovery Consortium</title><link>https://asapdiscovery.org/</link><description>Recent content in AI-driven Structure-enabled Antiviral Platform (ASAP) on ASAP Discovery Consortium</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Wed, 17 Jun 2020 00:00:00 +0000</lastBuildDate><atom:link href="https://asapdiscovery.org/index.xml" rel="self" type="application/rss+xml"/><item><title>Jun 17, 2020 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2020-06-17-minutes/</link><pubDate>Wed, 17 Jun 2020 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2020-06-17-minutes/</guid><description>The [Open Force Field Consortium Advisory Board] met on June 17, 2020. The minutes are summarized as follows:
Change in OpenFF leadership Lee-Ping Wang announced that he will step down from the leadership role in OpenFF on July 15, 2020. This decision is primarily driven by a desire to spend more time on research and exploration of new scientific decision and to reduce his involvement in the management duties of the Initiative.</description></item><item><title>May 20, 2020 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2020-05-20-minutes/</link><pubDate>Wed, 20 May 2020 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2020-05-20-minutes/</guid><description>The [Open Force Field Consortium Advisory Board] met on May 20, 2020. The minutes are summarized as follows:
Infrastructure update J. Wagner gave an infrastructure update based on his talk presented during the recent virtual Third Open Force Field Workshop on May 4-5, 2020. Suggestions for QCArchive to incorporate some quality control information about molecular geometries and potential connectivity changes. At the moment, OpenFF is trying to generate SMILES before and after calculations.</description></item><item><title>Apr 15, 2020 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2020-04-15-minutes/</link><pubDate>Wed, 15 Apr 2020 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2020-04-15-minutes/</guid><description>The [Open Force Field Consortium Advisory Board] met on April 15, 2020. The minutes are summarized as follows:
Brief Update D. Mobley provided a brief progress update since the last meeting. S. Boothroyd is working on a feasibility study for optimal combinations of physical properties for fitting nonbonded parameters. openff-1.2.0 release will contain an improved QM training set with a more systematic approach to molecule selection, while Sage will include the LJ refit based on the feasibility study.</description></item><item><title>Mar 19, 2020 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2020-03-18-minutes/</link><pubDate>Wed, 18 Mar 2020 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2020-03-18-minutes/</guid><description>The [Open Force Field Consortium Advisory Board] met on March 18, 2020. The minutes are summarized as follows:
The meeting has been cancelled due to workplace disruptions caused by the COVID19 outbreak. The in-person meeting has been postponed for November 9-10, while the meeting in May will be virtual. Katharina Meier and Thomas Fox have been confirmed as the industry representatives on the Governing Board for the next 6 months. The election period and voting protocol will be discussed during the next meeting.</description></item><item><title>Feb 19, 2020 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2020-02-19-minutes/</link><pubDate>Wed, 19 Feb 2020 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2020-02-19-minutes/</guid><description>The [Open Force Field Consortium Advisory Board] met on February 19, 2020. The minutes are summarized as follows:
Next FF release plans I. Craig (BASF) reported some issues with nitrogen parameters in tetrazoles, and H. Jang has updated a couple of parameters in the recently released minor release - openff-1.1. D. Mobley presented some benchmarking results from V. Lim’s study of conformer energies and geometries. For geometry comparison, RMSD and torsion fingerprinting deviation (TFD) were used as similarity measures.</description></item><item><title>Jan 15, 2020 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2020-01-15-minutes/</link><pubDate>Wed, 15 Jan 2020 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2020-01-15-minutes/</guid><description>The [Open Force Field Consortium Advisory Board] met on January 15, 2020. The minutes are summarized as follows:
Open Forcefield Advisory Board Meeting Minutes – Jan 19, 2020 Protein-ligand benchmarking D. Hahn gave an update on his progress with protein-ligand benchmarking of Parsley &amp;ndash; he is currently working on developing a repository for storing and presenting data used for protein-ligand benchmarking studies, which stores only primary data reported in cited publications (derived data, for example dG, is converted on the fly from IC50, Kd, etc) D.</description></item><item><title>Nov 19, 2019 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2019-11-19-minuted/</link><pubDate>Tue, 19 Nov 2019 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2019-11-19-minuted/</guid><description>The [Open Force Field Consortium Advisory Board] met on November 19, 2019. The minutes are summarized as follows:
Open Forcefield Advisory Board Meeting Minutes – Nov 19, 2019 Personnel update Y. Qiu and D. Slochower have left their positions at UC Davis and UC San Diego, respectively S. Boothroyd moved from the Chodera lab at MKSCC, New York to the Shirts lab at CU Boulder, Colorado OpenFF is hiring more personnel, primarily software scientists OFF toolkit update Version 0.</description></item><item><title>Oct 16, 2019 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2019-10-16-minutes/</link><pubDate>Wed, 16 Oct 2019 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2019-10-16-minutes/</guid><description>The Open Force Field Consortium Advisory Board had an in-person meeting during the Consortium workshop in San Diego (Aug 30-31, 2091), discussing research questions of interest and potential future directions for the Open Force Field Initiative. This and other discussions held during the meeting made a basis for the roadmap for Year 2. This was the joint August/September meeting.
The minutes from the meeting held on Oct 16, 2019 are summarized as follows:</description></item><item><title>Jul 17, 2019 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2019-07-17-minutes/</link><pubDate>Tue, 23 Jul 2019 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2019-07-17-minutes/</guid><description>The Open Force Field Consortium Advisory Board met on July 17, 2019. The minutes are summarized as follows:
Open Forcefield Advisory Board Meeting Minutes – July 17, 2019 The Advisory Board format was slightly changed on this occasion - the report about the latest development was sent before the meeting to leave more time for questions and discussions. We will test this new format during the next few meetings. Feedback and comments are welcome!</description></item><item><title>Jun 13, 2019 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2019-06-13-minutes/</link><pubDate>Thu, 13 Jun 2019 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2019-06-13-minutes/</guid><description>The Open Force Field Consortium Advisory Board met on 13 June, 2019. The minutes are summarized as follows:
Open Forcefield Advisory Board Meeting Minutes – June 13, 2019 First optimized force field (D. Mobley):
Aiming to have the first force field released by Sept 1 and evaluations performed by Oct 1. Specific discussion about it takes place in #release-1 channel on Slack.
Types: The same typing tree as smirnoff99Frosst will be used, but the differentiable parameters in (a subset of) torsion, valence, and Lennard-Jones parameters will be optimized;</description></item><item><title>May 15, 2019 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2019-05-15-minutes/</link><pubDate>Wed, 15 May 2019 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2019-05-15-minutes/</guid><description>The Open Force Field Consortium Advisory Board met on 15 May, 2019. The minutes are summarized as follows:
Open Forcefield Advisory Board Meeting Minutes – May 15, 2019 Overview of the roadmap for the remaining time of Year 1 and the accomplishments made so far (J. Chodera).
Torsions update (L.-P. Wang):
The selected set of molecules for initial torsion scanning contains 486 small and chemically diverse molecules provided by Roche (less than 30 heavy atoms)- “Roche set”- more fragments will be added to this set in the future;</description></item><item><title>April 17, 2019 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2019-04-17-minutes/</link><pubDate>Wed, 17 Apr 2019 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2019-04-17-minutes/</guid><description>The Open Force Field Consortium Advisory Board met on 17 April 2019. The minutes are summarized as follows:
Open Forcefield Advisory Board Meeting Minutes – 17 April 2019 K. Condic-Jurkic to take over future agenda planning with input from D. Kuhn, I. Craig, A. Narayanan Release update by Jeff Wagner: 0.2.1 bugfix release on the 12th after initial 0.2.0 release on 8th Version numbers indicate API is still in flux, there may be function call changes, etc.</description></item><item><title>March 20, 2019 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2019-03-20-minutes/</link><pubDate>Wed, 20 Mar 2019 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2019-03-20-minutes/</guid><description>The Open Force Field Consortium Advisory Board met on 20 March, 2019. The minutes are summarized as follows:
Open Forcefield Advisory Board Meeting Minutes – March 20, 2019 Status Updates: OFFI NIH proposal submitted and available publicly Hiring update: Karmen Condic-Jurkic starts April 1 as half-time scientific coordinator/project manager Interviews ongoing for bespoke torsion fitting and potentially electrostatics role Open Force Field Toolkit update: Alpha release slated for April 2 Will contain RDKit backend support in abstracted cheminformatics structure (allowing future support for alternative cheminformatics packages to be easily added) Supposed to give same results regardless of RDKit or OpenEye (tested with ~2k molecules from eMolecules to have same energies, forces, and force terms) Differences in aromaticity models could result in some differences in corner cases We are adding a “paranoid mode” so we can detect differences between toolkits that arise when building force fields SDF with standardized tags will be the supported method for importing molecules with custom charges OpenEye and RDKit on-board with standardized tags for charges There may have been minor changes to XML forcefield format since the January preview release Changes are summarized here OFFI hope is to have weekly/biweekly bugfix or feature releases and conda package updates Partners and users are directed to use the Github issue tracker to report issues or problems Technical questions – Desmond support How is Desmond currently used by Partners?</description></item><item><title>February 20, 2019 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2019-02-20-minutes/</link><pubDate>Wed, 20 Feb 2019 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2019-02-20-minutes/</guid><description>The Open Force Field Consortium Advisory Board met on 20 February, 2019. The minutes are summarized as follows:
Open Forcefield Advisory Board Meeting Minutes – February 20, 2019 Next release of toolkit currently being tested and finished Workflow documentation Next item on to-do list Call for additional desired workflows to be posted in #documentation channel Industry compound additions to parameterization sets Starting small – current focus is finding parameters in need of optimization by looking for discrepancies between current forcefields when minimizing structures Industry partners should identify particularly high priority chemical space for initial parameterization Compounds/fragments to be sent via Slack or GitHub BI has SureChembl dump and scripts that may be able to be shared.</description></item><item><title>January 23, 2019 Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2019-01-23-minutes/</link><pubDate>Wed, 23 Jan 2019 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2019-01-23-minutes/</guid><description>The Open Force Field Consortium Advisory Board met on 23 Jan 2019. The minutes are summarized as follows:
Open Forcefield Advisory Board Meeting Minutes – January 23, 2019 RDKit Integration Key infrastructure seems to be working Currently implementing testing to make sure energies/parameters are same between RDKit and OpenEye toolkit backends Documentation being worked on Limited to SDF file format initially RDKit support being added initially for OpenFF toolkit, not for other packages being used internally for parameter development Bespoke torsion parameterization tool will be able to use RDKit or other wholly open-source backend Workflows Workflow documentation / example requests should be posted to #documentation Slack channel Some suggested workflows from agenda and discussion: Parameterization of protein-ligand system using SMIRNOFF Conformer energy evaluation Minimization of multiple ligands from SDF file (is this with protein, without, both?</description></item><item><title>January 7-8, 2019 Consortium Workshop</title><link>https://asapdiscovery.org/consortium/minutes/2019-01-07-minutes/</link><pubDate>Mon, 07 Jan 2019 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2019-01-07-minutes/</guid><description>Minutes: Attending: All PIs and software scientists; most industry partners, postdocs, and students (including via Zoom); academic and industry community members
Visit the agenda page for more details of the workshop.</description></item><item><title>October 29, 2018 Joint Governing/Advisory Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2018-10-29-minutes/</link><pubDate>Mon, 29 Oct 2018 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2018-10-29-minutes/</guid><description>Minutes: Attending: All PIs, both governing board members, and most advisory board members, via Zoom.
Short-term roadmap/minimum viable product: In general folks are supportive of current effort plans. However, there was consensus we need a tool for bespoke parameterization of molecules, especially internal molecules which might not be able to be disclosed to the larger effort, as part of our minimum viable product.
Funding/financials: Currently we have eight partners on board (with openforcefield.</description></item><item><title>October 11, 2018 Governing Board Meeting</title><link>https://asapdiscovery.org/consortium/minutes/2018-10-11-minutes/</link><pubDate>Thu, 11 Oct 2018 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/consortium/minutes/2018-10-11-minutes/</guid><description>Agenda: October meeting draft agenda and start time January meeting location Maat hiring Slack Funding processing update/onboarding update Involvement with science meetings (subprojects) and project planning Discuss blog posts? Yes, just get sub-groups to do brief updates after meetings; better for keeping people up to date. Minutes: Attending: All PIs except Shirts, and both industry members, Thomas Fox and Katharina Meier
Shared the detailed budget outline Google Doc and went over the personnel who would be involved and their distribution across different locations, $ amounts, etc.</description></item><item><title>Viral Families</title><link>https://asapdiscovery.org/outputs/viral-families/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/viral-families/</guid><description>ASAP aims to discover direct-acting antivirals with broad antiviral activity within a viral family, but the difficulty of achieving this goal means that some of our program objectives are more narrowly focused on viral family members of greatest pandemic concern.
coronaviridae Coronavirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.
flaviviridae Flavivirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.</description></item><item><title>Software</title><link>https://asapdiscovery.org/outputs/software/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/software/</guid><description>Software produced by ASAP.
argos [GitHub] A web-based visualization tool for viewing DMS data on protein structures that allows users to generate and share these views using a web UI. See &amp;lsquo;choppa&amp;rsquo; package below. Contributing Projects and Cores: Project 2 Computational Chemistry Core asapdiscovery [GitHub] [Documentation] Monorepository for running computational chemistry project support for ASAP&amp;rsquo;s viral targets, including docking, free energy calculations, chemoinformatics and machine learning. Contributing Projects and Cores: Project 5 Computational Chemistry Core choppa [GitHub] [Documentation] A Python library for visualizing Deep Mutational Scanning data and other fitness data directly onto protein structures to enable fitness-informed decision-making in medicinal chemistry workflows in P2-P5 of ASAP&amp;rsquo;s drug discovery pipeline.</description></item><item><title>Targeting Opportunities</title><link>https://asapdiscovery.org/outputs/targeting-opportunities/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/targeting-opportunities/</guid><description>A targeting opportunity provides an overview of the opportunity for targeting new antivirals to a specific target protein and mode of action. This overview is intended to summarize relevant information for drug hunters, including the relevant domain and binding sites to target, notable chemical matter, rationale for antiviral effects, and other useful information in prosecuting a discovery compaign aginst the target.
Targeting Opportunity: SARS-CoV-2 / MERS-CoV Mpro protease [Targeting Opportunity] Contributing Projects and Cores: Project 1 Project 5 [2023-03-19] Initial draft [2024-04-29] Major update of the targeting opportunity covering clinical background, history of outbreaks, viral biology, target biochemistry, phylogenetic analysis, etc.</description></item><item><title>Molecules</title><link>https://asapdiscovery.org/outputs/molecules/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/molecules/</guid><description>SARS-CoV-2/MERS-CoV Mpro lead optimization assay data [metadata] [(negative) biochemical and liver microsome assay data [Oct 2023]] [(negative) biochemical and liver microsome assay data [Mar 2024]] [SARS-CoV-2 Mpro assay protocol] [MERS-CoV Mpro assay protocol] This data release contains assay data for compounds ASAP is not pursuing toward nomination of a development candidate as part of this discovery program. Contributing Projects and Cores: Project 5 Biochemical Assay Core Data Core [2023-04-30] Initial public release of negative biochemical activity data for 182 molecules.</description></item><item><title>Structures</title><link>https://asapdiscovery.org/outputs/structures/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/structures/</guid><description>MERS-CoV/SARS-CoV-2 Mpro protease ASAP-COV-MPRO XChem crystallographic fragment screen of SARS-CoV-2 Mpro xray-fragment-screen [ 2020-03-18 ] Contributing Projects and Cores: Project 2 Structural Biology Core We performed an exhaustive crystallographic fragment screen to probe the Mpro active site, and to identify opportunities for fragment merging or growing. Additionally, a library of mild electrophilic fragments was screened by mass spectrometry for probing the binding properties around the active site cysteine. Overall, a total of 1742 soaking and 1139 co-crystallization experiments resulted in 1877 mounted crystals.</description></item><item><title>Publications</title><link>https://asapdiscovery.org/outputs/publications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/publications/</guid><description>ASAP aims to publish preprints to ensure our scientific advances are rapidly and openly available.</description></item><item><title>Analysis of Viral Mutations</title><link>https://asapdiscovery.org/outputs/circulating-variants/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/circulating-variants/</guid><description>Analysis of circulating variants of SARS-CoV-2 nsp5 Mpro protease [interactive viewer] [bioRxiv preprint] Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants Contributing Projects and Cores: Project 1 [2023-01-31] Preprint and interactive mutation viewer posted. Analysis of circulating variants of SARS-CoV-2 nsp15 endoribonuclease [interactive viewer] [bioRxiv preprint] Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants Contributing Projects and Cores: Project 1 [2023-01-31] Preprint and interactive mutation viewer posted.</description></item><item><title>Target Product Profiles (TPPs)</title><link>https://asapdiscovery.org/outputs/target-product-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-product-profiles/</guid><description>A Target Product Profile (TPP) describes the desired characteristics of a drug product aimed to treat a particular disease or set of diseases.
All ASAP TPPs are draft TPPs intended to help guide the development of target candidate profiles (TCPs) for antiviral discovery within the ASAP Discovery Consortium. ASAP works with stakeholders around the globe (such as the World Health Organization) to align TPPs to ensure they meet the needs of communities and fulfill our mission of global, equitable, and affordable access to antiviral therapies.</description></item><item><title>Target Enabling Packages (TEPs)</title><link>https://asapdiscovery.org/outputs/target-enabling-packages/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-enabling-packages/</guid><description>A Target Enabling Package (TEP) is a complete data package needed to enable structure-based drug discovery against an antiviral target. Pioneered by the Structural Genomics Consortium, each TEP contains relevant protein constructs and plasmid resources for one or more viral family members, protein expression and purification protocols, crystallization conditions, structures from an X-ray fragment screen at the Diamond Light Source XChem facility, small molecule hits, and biochemical assay protocols with at least one validated inhibitor with quantifiable activity.</description></item><item><title>Assay Cascades</title><link>https://asapdiscovery.org/outputs/assay-cascades/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-cascades/</guid><description>An assay cascade is a defined set of assays and progression criteria used by a drug discovery program to achieve its Target Candidate Profile (TCP) goals in a time- and cost-effective manner.
Assay cascade for MERS-CoV / SARS-CoV-2 oral antiviral [Asay Cascade (lead optimization)] Contributing Projects and Cores: Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2022-06-01] Initial draft DENV/ZIKV NS2B/3 3C protease [Assay Cascade] Assay cascade for DENV/ZIKV NS2B/3 3C Protease oral antiviral Contributing Projects and Cores: Project 3 Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2023-12-23] Initial draft EV-D68 / EV-A71 3C Protease Assay Cascade [Assay Cascade] Assay cascade for EV-D68 / EV-A71 3C Protease oral antiviral Contributing Projects and Cores: Project 3 Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2022-07-14] Initial draft Assay cascade for SARS-CoV-2 nsp3 Mac1 macrodomain oral antiviral [Assay Cascade (fragment-to-lead)] Partial SARS-CoV-2 nsp3 Mac1 macrodomain assay cascade for lead nomination Contributing Projects and Cores: Project 3 Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2022-06-01] Initial draft Assay cascade for SARS-CoV-2 Mpro oral antiviral [Assay Cascade (lead optimization)] Assay cascade for lead optimization campaign for SARS-CoV-2 noncovalent oral inhibitor from the COVID Moonshot [2020-03-23] Initial draft for COVID Moonshot</description></item><item><title>Assay Protocols</title><link>https://asapdiscovery.org/outputs/assay-protocols/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-protocols/</guid><description>ASAP frequently needs to develop or scale its own biochemical assay protocols to drive discovery programs. Whenever possible, we share these protocols through protocols.io, an industry standard platform for sharing and annotating assay protocols.
MERS-CoV main protease (Mpro) activity fluorescence dose response biochemical assay [assay protocol] This is a functional, biochemical assay used to identify treatments for viral infectious disease in MERS 3C-like main viral protease. Utilizing a direct enzyme activity measurement method, the experiment was performed in a 384-well plate reading the fluorescence intensity.</description></item><item><title>Target Candidate Profiles (TCPs)</title><link>https://asapdiscovery.org/outputs/target-candidate-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-candidate-profiles/</guid><description>A Target Candidate Profile (TCP) describes the objectives an ASAP drug discovery program aims to achieve to produce a preclinical candidate. Our TCPs are informed by the corresponding Target Product Profiles (TPPs) for the corresponding disease.
MERS-CoV / SARS-CoV-2 MPro protease oral inhibitor [Target Candidate Profile] Contributing Projects and Cores: Project 5 [2023-03-01] Initial draft DENV/ZIKV NS2B/3 protease oral inhibitor draft [Target Candidate Profile] Contributing Projects and Cores: Project 3 Project 5 [2023-03-01] Initial draft [2023-05-11] Consolidate DENV/ZIKV EV-D68/A71 3C protease oral inhibitor [Lead Transition Profile] [Target Candidate Profile] Contributing Projects and Cores: Project 3 Project 5 [2023-06-22] Initial drafts EV-D68/A71 VP1 capsid assembly oral inhibitor [Lead Transition Profile] [Target Candidate Profile] Contributing Projects and Cores: Project 3 Project 5 [2023-12-15] Initial drafts SARS-CoV-2 nsp3 Mac1 macrodomain oral inhibitor [Target Candidate Profile for lead nomination] Contributing Projects and Cores: Project 3 Project 5 [2023-03-01] Initial draft SARS-CoV-2 Oral MPro protease inhibitor [Target Candidate Profile] Contributing Projects and Cores: Project 5 [2020-04-01] Initial draft</description></item><item><title>Preclinical programs</title><link>https://asapdiscovery.org/outputs/preclinical/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/preclinical/</guid><description>SARS-CoV-2 Mpro protease See the COVID Moonshot preclinical program.</description></item><item><title>Investigational New Drug (IND) filings</title><link>https://asapdiscovery.org/outputs/investigational-new-drugs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/investigational-new-drugs/</guid><description>ASAP does not yet have any programs that have reached Investigational New Drug (IND) status.</description></item><item><title>Clinical trials</title><link>https://asapdiscovery.org/outputs/clinical-trials/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/clinical-trials/</guid><description>ASAP does not currently have any programs that have reached clinical trials.</description></item><item><title>New Drug Approvals</title><link>https://asapdiscovery.org/outputs/new-drug-approvals/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/new-drug-approvals/</guid><description>ASAP does not currently have any programs that have reached New Drug Approval (NDA) status.</description></item><item><title/><link>https://asapdiscovery.org/outputs/img/icons/readme/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/img/icons/readme/</guid><description>Icons from The Noun Project Icons are CC-BY from The Noun Project
Credits (for CC-BY acknowledgments) assay-cascade.png : noun-chemistry-2954755 : Chemistry by Icon Factory from Noun Project clinical-trails.png : noun-medical-1053629 : medical by Raymond from Noun Project data.png : noun-save-5021426 : Save by Cetha Studio from Noun Project disease.png : noun-medical-3923610 : medical by Royyan Wijaya from Noun Project DMS.png : noun-mutation-4374976 : mutation by Adrien Coquet from Noun Project hit-to-lead.</description></item><item><title/><link>https://asapdiscovery.org/pipeline/img/icons/readme/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/pipeline/img/icons/readme/</guid><description>Icons from The Noun Project Icons are CC-BY from The Noun Project
Credits (for CC-BY acknowledgments) assay-cascade.png : noun-chemistry-2954755 : Chemistry by Icon Factory from Noun Project clinical-trails.png : noun-medical-1053629 : medical by Raymond from Noun Project data.png : noun-save-5021426 : Save by Cetha Studio from Noun Project disease.png : noun-medical-3923610 : medical by Royyan Wijaya from Noun Project DMS.png : noun-mutation-4374976 : mutation by Adrien Coquet from Noun Project hit-to-lead.</description></item><item><title>Awards</title><link>https://asapdiscovery.org/awards/rfa/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/awards/rfa/</guid><description>Applications for the ASAP AViDD Center Developmental Research Project Awards and Mentored Project Awards are currently under review with awards expected to be announced by April 2023.
Funds for these awards are provided by the National Institutes of Health under award number U19AI171399 through the NIAID Antiviral Drug Discovery (AViDD) U19 Program.
Developmental Research Project Awards Funding Opportunity Title
AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium Developmental Project Award Program</description></item><item><title>Developmental and Mentored Awards</title><link>https://asapdiscovery.org/awards/projects/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/awards/projects/</guid><description>Developmental Research Projects Applications for the ASAP AViDD Center Developmental Research Project Awards and Mentored Project Awards closed on 13 Jan 2023. After scoring applications by our Scientific Advisory Board, NIAID approved the following awards, which were issued on 1 May 2023.
Funds for these awards are provided by the National Institutes of Health under award number U19AI171399 through the NIAID Antiviral Drug Discovery (AViDD) U19 Program.
Defining mutational constraints of ASAP-prioritized SARS-CoV-2 target proteins via multiplexed, yeast-based cDNA Project Leader: Farren Isaacs, Yale University, New Haven, CT</description></item><item><title>FAQ</title><link>https://asapdiscovery.org/privacy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/privacy/</guid><description>ASAP Discovery Consortium Privacy Policy This Privacy Policy explains how ASAP Discovery Consortium (&amp;ldquo;we,&amp;rdquo; &amp;ldquo;us,&amp;rdquo; or &amp;ldquo;our&amp;rdquo;) collects, uses, and safeguards your personal information when you visit our website and interact with our services. We are committed to protecting your privacy and complying with applicable data protection laws, including the General Data Protection Regulation (GDPR).
By using the ASAP Discovery Consortium website and services, you consent to the terms outlined in this Privacy Policy.</description></item><item><title>Open Science</title><link>https://asapdiscovery.org/open-science/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/open-science/</guid><description>Authors: Pascale Boulet, ASAP IP Strategy Consultant, Intellectual Property &amp;amp; Access Leader, DNDi
Dr Ed Griffen, ASAP Lead Optimization Project Lead, MedChemica Consultancy Ltd
Our approach to open science and intellectual property is described in detail in our formal policy:
Griffen, E., &amp;amp; Boulet, P. (2024). ASAP Policy on Intellectual Property Management and Open Science Disclosure (1.0). Zenodo. https://doi.org/10.5281/zenodo.12191567
Below, we provide a brief summary of the main principles of our approach to open science:</description></item></channel></rss>